Alpha 2.0
Login Register
» Authors » Timur Davlyatshin

Timur Davlyatshin

Explore the profile of Timur Davlyatshin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 56
Followers 0
Related Specialties
General Medicine
Allergy & Immunology
Pediatrics
Top 10 Co-Authors
Marina Stukova
Markhabat Kassenov
Gulbanu Sarsenbayeva
Berik Khairullin
Ilyas Kulmagambetov
Zhanna Buzitskaya
Timur Issagulov
Mukhit Orynbayev
Kulyaisan Sultankulova
Ainur Nurpeisova
Published In
Hum Vaccin Immunother
EClinicalMedicine
J Med Virol
Ann Pediatr Endocrinol Metab
Affiliations
Soon will be listed here.
Recent Articles
1.
Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy
Altynbekova S, Abylaiuly Z, Bolshakova S, Davlyatshin T, Aimakhanova A
Ann Pediatr Endocrinol Metab . 2024 Nov; 29(5):325-336. PMID: 39506346
Purpose: In this article, we report the results of a survey investigating post-coronavirus disease 2019 (COVID-19) syndrome in patients with type 2 diabetes mellitus and the impacts of vaccination on...
2.
Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up
Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, et al.
EClinicalMedicine . 2022 Jun; 50:101526. PMID: 35770251
Background: Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, further necessitating the use of effective licensed vaccines. Methods: From Dec 25, 2020, to July 11,...
3.
Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months...
Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, et al.
EClinicalMedicine . 2021 Aug; 39:101078. PMID: 34414368
Background: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials...
4.
Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan
Sarsenbayeva G, Issagulov T, Kassenov M, Abitay R, Orynbayev M, Stukova M, et al.
Hum Vaccin Immunother . 2020 Feb; 16(8):1791-1797. PMID: 32048890
Background: The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on...
5.
Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults
Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, et al.
Hum Vaccin Immunother . 2017 Nov; 14(3):609-614. PMID: 29112488
Background: The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on...
6.
Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial
Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, et al.
J Med Virol . 2017 Aug; 90(1):41-49. PMID: 28842994
The producers of influenza vaccines are not capable today to meet the global demand for an influenza vaccine in case of pandemic, so the World Health Organization recommends to develop...